Trinity Biotech stock rises on successful CGM calibration-free trial

Published 12/08/2025, 14:12
© Reuters.

Investing.com -- Trinity Biotech plc (NASDAQ:TRIB) stock rose 4.4% following the company’s announcement of positive clinical trial results for its next-generation continuous glucose monitoring (CGM) technology.

The biotechnology company reported that its redesigned needle-free glucose sensor successfully delivered accurate glucose readings across a full 15-day wear period without requiring finger-stick calibration. This technical breakthrough represents a significant milestone in the development of Trinity’s CGM+ platform, which aims to reduce costs compared to current market leaders by utilizing a modular design with fewer disposable components.

"This milestone represents the most significant technical achievement since we began redevelopment of our acquired CGM technology," said John Gillard, CEO of Trinity Biotech. "The elimination of the requirement for finger-stick calibration was achieved through a combination of sensor design modifications, refined signal processing, and proprietary enhancements to sensor operation."

The company’s CGM+ device is designed to integrate multiple health metrics including glucose monitoring, heart activity, body temperature, and physical activity data in a single wearable biosensor. Trinity Biotech is positioning its technology as a more affordable alternative in the growing CGM market, which is projected to expand from approximately $13 billion in 2025 to approximately $28 billion by 2030.

The successful trial results address what the company described as "the most uncertain technical hurdle" in its development process, potentially clearing a path toward commercialization and regulatory approval for the CGM+ platform.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.